IFNG and neoplasm: The personalized neoantigen vaccine “NeoVax”, which combines patient-specific neoantigens identified from tumor sampling, has successfully generated immune responses characterized by an increase in interferon-gamma (IFN-γ) producing T-cells and intratumoral T-cell infiltration [60].